These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37671290)

  • 1. Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits.
    Montagner PSS; Medeiros W; da Silva LCR; Borges CN; Brasil-Neto J; de Deus Silva Barbosa V; Caixeta FV; Malcher-Lopes R
    Front Psychiatry; 2023; 14():1210155. PubMed ID: 37671290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature.
    Bilge S; Ekici B
    J Cannabis Res; 2021 Dec; 3(1):53. PubMed ID: 34911567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CBD-Enriched
    Fleury-Teixeira P; Caixeta FV; Ramires da Silva LC; Brasil-Neto JP; Malcher-Lopes R
    Front Neurol; 2019; 10():1145. PubMed ID: 31736860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.
    Stolar O; Hazan A; Vissoker RE; Kishk IA; Barchel D; Lezinger M; Dagan A; Treves N; Meiri D; Berkovitch M; Kohn E; Heyman E
    Front Pharmacol; 2022; 13():977484. PubMed ID: 36249785
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management.
    Mazza JAS; Ferreira LS; Martins-Vieira AF; Beserra DDL; Rodrigues VA; Malcher-Lopes R; Caixeta FV
    Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid treatment for the symptoms of autism spectrum disorder.
    Aran A; Cayam Rand D
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
    Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
    BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
    Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
    [No Abstract]   [Full Text] [Related]  

  • 13. Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland.
    Zürcher K; Dupont C; Weber P; Grunt S; Wilhelm I; Eigenmann DE; Reichmuth ML; Fankhauser M; Egger M; Fenner L
    Eur J Pediatr; 2022 Jan; 181(1):335-347. PubMed ID: 34309706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study.
    Ma L; Platnick S; Platnick H
    Cureus; 2022 Aug; 14(8):e28442. PubMed ID: 36176817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cannabinoids in hair: Indicators for illegal vs CBD-rich cannabis use.
    Casati S; Angeli I; Bergamaschi RF; Ravelli A; Colombo G; Binelli G; Minoli M; Orioli M
    Forensic Sci Int; 2022 Apr; 333():111237. PubMed ID: 35228140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio.
    Zeyl V; Sawyer K; Wightman RS
    Subst Use Misuse; 2020; 55(8):1223-1227. PubMed ID: 32124675
    [No Abstract]   [Full Text] [Related]  

  • 19. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
    Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
    Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THC-Reduced
    Bartkowiak-Wieczorek J; Mądry E; Książkiewicz M; Winkler-Galicki J; Szalata M; Szalata M; Jiménez UE; Wielgus K; Grześkowiak E; Słomski R; Bienert A
    Nutrients; 2023 Jun; 15(12):. PubMed ID: 37375550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.